Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-09-17 16:22:42 ET · period of report 2026-09-15 · accession 0001228684-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-09-17 16:22 | 2026-09-15 | TARS | LINK WILLIAM J PHD | Dir | M - OptEx | — | +201 | 107.0K | +0.2% | — |
| DMT | 2026-09-17 16:22 | 2026-09-15 | TARS | LINK WILLIAM J PHD | Dir | S - Sale+OE | $78.38 | -12.5K | 94.5K | -12% | -$979.7K |
| DT | 2026-09-17 16:22 | 2026-09-15 | TARS | LINK WILLIAM J PHD | Dir | M - OptEx | $0.00 | -201 | 605 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-15 | M | A | 201 | — | 106,987 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. |
| 2 | Common | Common Stock | 2026-09-15 | S | D | 11,675 | $78.33 | 95,312 | D | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. (F3) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 3 | Common | Common Stock | 2026-09-15 | S | D | 759 | $79.00 | 94,553 | D | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. (F4) The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Common | Common Stock | 2026-09-15 | S | D | 66 | $80.01 | 94,487 | D | — | — | (F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025. |
| 5 | Derivative | Restricted Stock Units | 2026-09-15 | M | D | 201 | $0.00 | 605 | D | — · — to — | 201 Common Stock | (F5) Each RSU represents a contingent right to receive one share of the Company's common stock. (F6) RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. (F6) RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service. |